Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angel L Guerrero

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast CancerLuigi Formisano, Kimberly M Stauffer, Christian D Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Correction: ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 InhibitorsAngel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2018
ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 InhibitorsAngel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2025
Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast CancerMiguel Martín, Angel L Guerrero-Zotano, María E Pérez-López, et al.
Nature Communications|March 28, 2019
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerLuigi Formisano, Yao Lu, Alberto Servetto, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast CancerLuigi Formisano, Kimberly M Stauffer, Christian D Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Correction: ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 InhibitorsAngel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2018
ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 InhibitorsAngel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2025
Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast CancerMiguel Martín, Angel L Guerrero-Zotano, María E Pérez-López, et al.
Nature Communications|March 28, 2019
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerLuigi Formisano, Yao Lu, Alberto Servetto, et al.
Pageof 4